Juvena Therapeutics

Juvena Therapeutics is a clinical-stage biotechnology company pioneering the discovery and development of tissue-restorative biologics for chronic muscle and metabolic diseases, with an initial focus on myopathies and age-related decline.

Juvena's mission is to regenerate tissues to rejuvenate lives by discovering and developing powerful biologic drugs.

The company uses its proprietary, AI-enabled JuvNET platform to systematically map the therapeutic potential of the secretome -- the library of proteins secreted by human stem cells that naturally regulate tissue regeneration and repair. By leveraging this computational and biological approach, Juvena aims to unlock and engineer novel, protein-based drugs.

Their lead clinical-stage asset is JUV-161 for Myotonic Dystrophy Type 1 (DM1) and atrophy-related indications. In H2 2025, Juvena established a strategic partnership with Eli Lilly to discover novel secreted proteins and targets designed to enhance muscle metabolism, induce weight loss, and optimize body composition.